Platinum-based doublet chemotherapy is still the current standard of care for advanced non-small-cell lung cancer (NSCLC) patients who do not have an epidermal growth factor receptor mutation or anaplastic lymphoma kinase (ALK) rearrangement [2–4]. Here, EGFR is linked to non-small cell lung carcinoma.